New 227Th-labeled GPC3 antibody conjugate shows targeted antitumor activity in an HCC mouse model
Aug. 5, 2022
Alpha-therapy, in which alpha-particle-emitting radionuclides such as 227Th are delivered specifically to tumor tissues, is emerging as a novel strategy for targeted cancer therapy.
